Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.58 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.58 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611060 | 0.87 | MAPKAPK2 (0.46) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL31526691 | 0.87 | MAPKAPK2 (0.46) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL2619271 | 0.77 | RPS6KA3 (0.64) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL9198062 | 0.75 | CYP11B1 (0.47) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL21388615 | 0.75 | MAPKAPK2 (0.47) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL782851 | 0.74 | RPS6KA3 (0.64) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL7757513 | 0.74 | RPS6KA3 (0.64) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL706811 | 0.74 | MAPKAPK2 (0.64) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL19519842 | 0.74 | MAPKAPK2 (0.64) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL19300290 | 0.73 | MAPKAPK2 (0.58) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2022000443-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-01-06 | — | — | WO | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20200048195-A1 | SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-02-13 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | Epizyme, Inc. (US) | 2017-08-31 | — | — | US | disclosed |
| US-9073927-B2 | Inhibitors of PI3 kinase | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2015-07-07 | — | — | US | disclosed |
| US-8987280-B2 | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7893059-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7846929-B2 | Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents | GENENTECH, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PIK3CB, PIK3C2B | MAPKAPK2 91/4885RPS6KA3 85/4885CSNK2A1 236/4885 |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | MAPKAPK2 2873/4885RPS6KA3 2635/4885CSNK2A1 2696/4885 |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | MAPKAPK2 125/4885RPS6KA3 516/4885CSNK2A1 658/4885 |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | MAPKAPK2 612/4885RPS6KA3 622/4885CSNK2A1 1518/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | MAPKAPK2 89/4885RPS6KA3 228/4885CSNK2A1 332/4885 |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PI4KB, PI4KA | MAPKAPK2 117/4885RPS6KA3 198/4885CSNK2A1 395/4885 |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | MAPKAPK2 142/4885RPS6KA3 337/4885CSNK2A1 659/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | MAPKAPK2 2713/4885RPS6KA3 2311/4885CSNK2A1 1213/4885 |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | SMYD3, SMYD2, SMURF2 | MAPKAPK2 2261/4885RPS6KA3 944/4885CSNK2A1 1287/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | MAPKAPK2 2501/4885RPS6KA3 1764/4885CSNK2A1 1110/4885 |
| US-20200048195-A1 | SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS | SMYD3, SMYD2, SMURF2 | MAPKAPK2 2261/4885RPS6KA3 944/4885CSNK2A1 1287/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | MAPKAPK2 194/4885RPS6KA3 339/4885CSNK2A1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.